Replies to post #118789 on Biotech Values

[DewDiligence]

Here’s the graphic on AMRN’s diluted share count you cited:



Since the warrants and options are so strongly in-the-money, they are almost the same as ordinary shares for valuation purposes, and hence your $2.8B market-cap figure is valid. Either AMRN’s management thinks the stock is overpriced, or the author of the article in #msg-62380759 is out to lunch.